Abstract Objective APPEASE is a phase I study to assess the safety. dosing. and efficacy of rivoceranib (a selective. small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. https://www.bekindtopets.com/hot-mega-Jeffers-Economy-600D-Royal-Blue-Teal-Plaid-Horse-Blanket-super-sale/